The US FDA has approved Bristol Myers Squibb’s new oral medicine, Cobenfy, for treating schizophrenia in adults. This approval introduces a novel pharmacological approach after more than 30 years. The drug will be available by late October at $1,850 per month before insurance and rebates. Clinical trials have shown significant improvement in symptoms compared to a placebo.
Related Posts
Reliance to commission first solar giga-factory in FY25
- staff
- August 11, 2024
- 0
Reliance Industries Ltd planned to commission its first solar giga-factory in the current fiscal. The plant aimed to manufacture 20GW of solar PV by 2024-25 […]
India’s holdings of US government securities reach record high in June
India increased its holdings of US government securities to a record $241.9 billion in June, up from $235.4 billion the previous year. Ranking 12th globally, […]
Top 10 biggest wealth creating stocks: Reliance Industries tops list; Adani Green emerges as fastest wealth creator, says MOFSL report
Reliance Industries topped the wealth creation charts for the sixth consecutive time, generating Rs 11,178 billion during 2019-24. Adani Green emerged as the fastest wealth […]